Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation

Core Insights - Hoth Therapeutics, Inc. has announced significant advancements in its proprietary antisense oligonucleotide (ASO) cancer drug candidate, HT-KIT, focusing on allergic and inflammatory diseases [1][4] Intellectual Property Developments - The company has filed amended claims with the U.S. Patent and Trademark Office for its lead ASO technology targeting MS4A6A and FcεRIβ, enhancing intellectual property protection for HT-KIT [2] - These refined claims position HT-KIT as a novel therapeutic platform with potential applications in treating conditions such as anaphylaxis, mastocytosis, and allergic asthma [2] Preclinical Studies - Hoth has initiated a GLP-compliant 4-week intravenous toxicity study in C57BL/6 mice, which includes a 14-day recovery period [3] - This preclinical study aims to evaluate the safety profile of HT-KIT and will involve multiple dose groups, detailed pathology assessments, and pharmacokinetic profiling [3] Future Development Plans - The company is committed to advancing HT-KIT toward clinical evaluation and is conducting additional preclinical studies to validate its efficacy and safety [4] - Plans are in place to initiate regulatory discussions for first-in-human trials as part of the development process [4]